Project description
Discovering new targets for prevention and cure of breast cancer
The mutagenesis mediated by the apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like (APOBEC) protein family is common in human cancers and observed in 15 % of primary and 25 % of recurrent breast cancer cases. Current studies show that APOBEC mutagenesis contributes to disease progression in all breast cancer stages, including the development of therapy resistance. The EU-funded AMBER project aims to uncover the mechanism of APOBEC mutagenesis induction and maintenance and use this knowledge to fight breast cancer. The objectives include understanding the purpose of APOBEC mutagenesis and its contribution to breast cancer progression. The project additionally posits that APOBEC mutagenesis is associated with a new type of tumour epitope and that targeting these novel neo-epitopes might provide an effective means to eradicate APOBEC-driven breast tumours.
Objective
APOBEC mutagenesis is a cellular mechanism by which genetic alterations are acquired somatically, driven by APOBEC enzyme family members. This mechanism is prominently observed in 15% of primary and 25% of recurrent breast cancer, the most common cause of cancer-related death in middle-aged women. Current evidence suggests APOBEC mutagenesis contributes to all disease stages, i.e. cancer initiation, progression and treatment resistance.
The core idea of the AMBER project is that unravelling the mechanism of APOBEC mutagenesis induction and maintenance will turn this mechanism into breast cancer’s Achilles heel. To prove this, I will answer several challenging research questions: Why is APOBEC mutagenesis operational in breast cancer? How does APOBEC contribute to disease progression? Can we target APOBEC mutagenesis or APOBEC driven tumours specifically?
First, I will reveal epidemiological and molecular evidence for factors inducing APOBEC mutagenesis in breast cancer. This may help to prevent APOBEC mutagenesis from occurring, potentially decreasing breast cancer incidence. Second, using global and single cell genomics, I will secure a link between APOBEC mutagenesis and disease progression, giving leads to delay progression. Third, I will exploit a potential vulnerability of APOBEC driven breast cancer, since I have found that these tumors may depend on a proficient homologous DNA repair (HR) pathway. When experimentally confirmed, targeting HR may extinguish APOBEC driven disease. Finally, I have observed that APOBEC mutagenesis associates with a profound immune response. I hypothesize that this is due to a new type of neo-epitopes being produced. If proven true, targeting these neo-epitopes provide another effective means to eradicate APOBEC driven tumors.
I am confident AMBER will provide the fundamental insights into APOBEC mutagenesis needed to turn it into an Achilles heel which may help to prevent, delay or cure APOBEC driven breast cancer.
Fields of science
Programme(s)
- HORIZON.1.1 - European Research Council (ERC) Main Programme
Topic(s)
Funding Scheme
HORIZON-AG - HORIZON Action Grant Budget-BasedHost institution
3015 GD Rotterdam
Netherlands